4D Advisors LLC Makes New $7.20 Million Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

4D Advisors LLC acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 200,000 shares of the medical device company's stock, valued at approximately $7,204,000. Tandem Diabetes Care comprises about 5.0% of 4D Advisors LLC's portfolio, making the stock its 5th biggest holding. 4D Advisors LLC owned about 0.30% of Tandem Diabetes Care as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after buying an additional 77,451 shares during the period. GW&K Investment Management LLC grew its stake in shares of Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after acquiring an additional 323,674 shares in the last quarter. Park West Asset Management LLC raised its holdings in shares of Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after purchasing an additional 530,000 shares during the last quarter. Stephens Investment Management Group LLC boosted its holdings in Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after purchasing an additional 281,327 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Tandem Diabetes Care by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,533,828 shares of the medical device company's stock valued at $55,261,000 after purchasing an additional 8,012 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on TNDM. Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Wells Fargo & Company lowered their target price on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a report on Thursday. Canaccord Genuity Group lifted their price objective on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research report on Thursday. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Finally, Stifel Nicolaus reduced their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a report on Thursday. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and a consensus target price of $39.81.

Insider Activity at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the stock in a transaction dated Friday, March 7th. The stock was bought at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM traded up $1.50 during midday trading on Friday, hitting $21.48. The stock had a trading volume of 1,992,970 shares, compared to its average volume of 1,498,767. The company's 50-day moving average price is $18.80 and its 200-day moving average price is $28.53. Tandem Diabetes Care, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The company has a market capitalization of $1.43 billion, a P/E ratio of -11.13 and a beta of 1.52.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The business had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company's revenue for the quarter was up 22.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.65) EPS. As a group, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.